Jeffrey S. Hackman - 09 Aug 2022 Form 4 Insider Report for Comera Life Sciences Holdings, Inc.

Reporting relationship: Chairman, President, and Chief Executive Officer., Director
Issuer ticker: N/A
Reported as of: 09 Aug 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Aug 2022, 18:14:07 UTC
Prior SEC filing: 14 Feb 2023
Next SEC filing: 12 Sep 2022
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey S. Hackman

Key filing fact

Jeffrey S. Hackman filed Form 4 for Comera Life Sciences Holdings, Inc. on 11 Aug 2022.

Key facts

This page summarizes Jeffrey S. Hackman's Form 4 filing for Comera Life Sciences Holdings, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Aug 2022, 18:14.

Change

Previous filing in this sequence was filed on 14 Feb 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CMRA transaction Derivative

Stock Option (Right to Purchase)

Award

Transaction value: $0
Shares: +300,000
Change %
Price: $0.000000
Shares after: 300,000
Date: 09 Aug 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 300,000
Exercise price: $2.77
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option shall vest over four (4) years, with twenty-five percent (25%) of the shares of Common Stock underlying the option vesting on August 9, 2023 and the remainder vesting in equal monthly installments thereafter.

SEC remarks

Chairman, President, and Chief Executive Officer.